Avidity Biosciences Inc

Insider sell‑offs at Avidity post‑Novartis merger are procedural cash‑exits, not a sign of distress—investors should watch integration, not panic.

Investor insight: Avidity Biosciences’ execs, led by Teresa McCarthy, sell‑to‑cover RSUs in a routine, schedule‑driven pattern that signals confidence in long‑term prospects while keeping liquidity tight.